Print this page
-
A First-in-Human, Open-Label, Phase 1/2 Dose-Escalation with Enrichment and
Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics,
Pharmacodynamics, and Antitumor activity of GIM-122 as a Single Agent in Adult
Subjects with Advanced Solid Malignancies
Protocol: 052401Principal Investigator:
- Sanjay Goel (Rutgers University)
Applicable Disease Sites: Any Site -
A032103: MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Protocol: 082401Principal Investigator:
- Biren Saraiya M.D (Rutgers University)
Applicable Disease Sites: Urinary Bladder -
A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib
Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations
Protocol: 082404Principal Investigator:
- Saum Ghodoussipour (Rutgers University)
Applicable Disease Sites: Urinary Bladder -
A Multicenter, Open-label, Phase 1/1b Dose Finding, Safety, and Pharmacokinetic Study of MBRC-101, an Anti-EphA5 Monomethyl Auristatin E (MMAE) Antibody Drug Conjugate, in Advanced Refractory Solid Tumors.
Protocol: 052402Principal Investigator:
- Sanjay Goel (Rutgers University)
Applicable Disease Sites: Any Site -
A Phase 2 Study of SNDX-5613 in Combination with Chemotherapy for Patients with Relapsed or Refractory KMT2A-Rearranged Infant Leukemia.
Protocol: 112402Principal Investigator:
- Richard Drachtman M.D. (Rutgers University)
Applicable Disease Sites: Leukemia, other -
Palbociclib and Binimetinib in RAS-Mutant Cancers
Protocol: 172403Principal Investigator:
- Shridar Ganesan MD, PhD (Rutgers University)
Applicable Disease Sites: Any Site